Premium
Lack of prognostic significance of serum DNA methylation of DAPK, MGMT, and GSTPI in patients with non‐small cell lung cancer
Author(s) -
Hoffmann A.C.,
Kaifi J.T.,
Vallböhmer D.,
Yekebas E.,
Grimminger P.,
Leers J.M.,
Izbicki J.R.,
Hölscher A.H.,
Schneider P.M.,
Metzger R.,
Brabender J.
Publication year - 2009
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21348
Subject(s) - dna methylation , methylation , medicine , lung cancer , oncology , grading (engineering) , real time polymerase chain reaction , stage (stratigraphy) , carcinoma , cancer , cancer research , pathology , dna , gene , gene expression , biology , genetics , ecology , paleontology
Background and Objectives To further improve the screening, diagnosis and therapy of patients with non‐small cell lung cancer (NSCLC) additional diagnostic tools are desperately warranted. Aim of this study was to investigate the potential of the DNA methylation of DAPK, MGMT, and GSTPI in serum of patients with NSCLC as a prognostic molecular marker in this disease. Methods Seventy‐six patients with NSCLC were included in this study. The analysis of DNA methylation in serum of patients was performed on pre‐operative samples. Following DNA isolation and bisulfite‐treatment, DNA methylation was analyzed by quantitative‐methylation‐specific real‐time PCR with β‐actin as the internal reference gene. Results DNA methylation was detectable with following frequencies: DAPK 68.4%, MGMT 7.9%, GSTPI 0%. There were no associations between DNA methylation status and histology, tumor stage, grading or gender detectable. With a mean follow‐up of 19.7 months the median survival was 26.3 months. There were no associations between the status of DNA methylation in patient's serum and prognosis detectable. Conclusion The analysis of DNA methylation in serum of patients with NSCLC by quantitative‐methylation‐specific real‐time PCR is technically feasible. Although our results suggest quantification of DNA methylation in serum not of prognostic significance in this disease, further studies are warranted to determine the future potential of this molecular approach. J. Surg. Oncol. 2009;100:414–417. © 2009 Wiley‐Liss, Inc.